Belacap Tablets (Sevelamer Carbonate)

Adult dose

This medication should be taken 3 times daily with meals. 1) Administration to patients not taking phosphate binders The recommended initial dose of this medication is 0.8g to 1.6g. Take 1~2 tablets with each meal according to the serum phosphorus level, as follows. Table 1. Initial dose in patients with chronic kidney disease not taking phosphate binders 5.5 - 7.5 ㎎/dL: 1 tablet per dose, 3 times daily with meals 7.5 ㎎/dL or higher: 2 tablets per dose, 3 times daily with meals 2) Switching patients taking sevelamer hydrochloride tablets to this medication When switching patients taking sevelamer hydrochloride tablets to this medication, use the same dose. Appropriate dose adjustment may be needed to achieve the target serum phosphorus level. The maximum daily dose of sevelamer carbonate studied in patients with chronic kidney disease receiving dialysis was 14g. 3) Switching patients taking calcium acetate preparations to this medication Table 2. Initial dose in patients with chronic kidney disease when switching from calcium acetate preparations to this medication Calcium acetate preparation (containing 667mg calcium acetate per tablet): 1 tablet per dose, 3 times daily — Dose of this medication: 1 tablet per dose, 3 times daily Calcium acetate preparation (containing 667mg calcium acetate per tablet): 2 tablets per dose, 3 times daily — Dose of this medication: 2 tablets per dose, 3 times daily Calcium acetate preparation (containing 667mg calcium acetate per tablet): 3 tablets per dose, 3 times daily — Dose of this medication: 3 tablets per dose, 3 times daily 4) Switching between sevelamer carbonate tablets and powder When switching between sevelamer carbonate tablets and powder, use the same dose. Appropriate dose adjustment may be needed to achieve the target serum phosphorus level. 5) Dose adjustment in all patients taking this medication If necessary, increase or decrease the dose of this medication by 0.8g at 2-week intervals, taken 3 times daily with meals, until the target serum phosphorus level is achieved.

This medication should not be used in patients with allergies to the active ingredient or excipients. Additionally, it should not be administered to patients with low serum phosphorus levels or bowel obstruction. Patients with narrowed intestines or severe constipation should be cautious, as this medication may swell in the intestines and cause serious problems such as bowel obstruction or perforation. During treatment, gastrointestinal symptoms such as vomiting, nausea, diarrhea, dyspepsia, abdominal pain, bloating, and constipation may occur. Particularly in patients undergoing peritoneal dialysis, there is a risk of peritonitis, so symptoms related to peritonitis should be monitored closely and appropriate treatment should be sought immediately. Patients with swallowing difficulties or issues with the medication getting lodged in the esophagus may safely use powder preparations instead. This medication does not contain calcium or alkaline components, so serum calcium levels should be monitored regularly, and calcium supplements should be taken if necessary. Long-term use may decrease the levels of fat-soluble vitamins A, D, E, and K as well as folic acid, so it is advisable to check vitamin status regularly and supplement if needed. This medication may interfere with the absorption of other oral drugs, so it should be taken at least 1 hour before or 3 hours after other medications. In particular, it should not be taken simultaneously with ciprofloxacin, and caution is needed for patients taking antiarrhythmics or antiepileptics. Pregnant women should only use this medication if the benefits of treatment outweigh the risks to the fetus. It is unclear whether this medication is secreted in breast milk, but since it is a non-absorbed medication, the likelihood of secretion is low. Safety and effectiveness in children under 18 years of age have not been established, so it is advisable not to use it in this age group. No special precautions are needed for the elderly, but it is advisable to start at an appropriate dose. If severe constipation, persistent abdominal pain, or vomiting occurs, immediately discontinue the medication and consult with a healthcare provider. This medication must be taken with food and should be swallowed whole without chewing or crushing. It should be stored in its original container, protected from moisture and direct sunlight.

vomiting, nausea, diarrhea, dyspepsia, abdominal pain, bloating, constipation, peritonitis, hypersensitivity, itching, rash, fecal obstruction, intestinal obstruction, bowel obstruction, intestinal perforation, hyperkalemia, hypercalcemia, acidosis, dizziness, headache, hypertension, hypotension, skin disorders, dysphagia, swallowing difficulties, severe gastrointestinal motility disorders, inflammatory gastrointestinal disorders, hypothyroidism, increased insulin levels

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. The storage temperature should be maintained between 1°C and 30°C.

Appearance

White or grayish oval film-coated tablets

Package unit

30 tablets/bottle, 180 tablets/bottle